Market revenue in 2024 | USD 292.4 million |
Market revenue in 2030 | USD 888.6 million |
Growth rate | 20.7% (CAGR from 2025 to 2030) |
Largest segment | Pre-commercial/ r&d scale |
Fastest growing segment | Commercial Scale |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-commercial/ R&D Scale, Commercial Scale |
Key market players worldwide | Miltenyi Biotec, Lonza Group Ltd, Fresenius SE & Co KGaA, Cytiva, Terumo Corp, Sartorius AG, ThermoGenesis Holdings Inc, Thermo Fisher Scientific Inc, Biospherix, Cellares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to automated and closed cell therapy processing systems market will help companies and investors design strategic landscapes.
Pre-commercial/ r&d scale was the largest segment with a revenue share of 92.2% in 2024. Horizon Databook has segmented the Asia Pacific automated and closed cell therapy processing systems market based on pre-commercial/ r&d scale, commercial scale covering the revenue growth of each sub-segment from 2018 to 2030.
Growing government and private investments, increasing healthcare needs, establishment of accelerated approval pathways are key drivers of the Asia Pacific market. Moreover, China is showed as the fast-growing market for cell therapy development.
Favorable regulatory scenario, mature infrastructure for clinical studies, and a booming ecosystem with government–industry collaboration is driving China’s cell and gene therapy development market. In addition, China has been ranked second in term clinical trials across the globe, with over 1,000 clinical trials either completed or ongoing.
Furthermore, Japan is anticipated to witness significant market growth due to rising clinical studies on cell therapies and the rising number of cell therapies advancing from clinical trials to regulatory approval. For instance, in October 2020, Novartis received approval from Japan’s Ministry of Health, Labor, and Welfare for the Foundation for Biomedical Research and Innovation to produce and supply Kymriah in the country.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific automated and closed cell therapy processing systems market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific automated and closed cell therapy processing systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account